Humoral Response to SARS-CoV-2 Vaccine of a Patient Receiving Methotrexate Treatment and Implications for the Need of Monitoring

Humoral Response to SARS-CoV-2 Vaccine of a Patient Receiving Methotrexate Treatment and Implications for the Need of Monitoring

We report a case of monitoring the antibody response to the BioNTech–Pfizer vaccine of a 50-year-old female diagnosed with rheumatoid arthritis undergoing treatment with methotrexate (MTX). Antibody levels were measured 21 days after dose 1 (i.e., on the day of dose 2) and then 8, 14 and 30 days aft...

Full description

Bibliographic Details
Main Authors: Krzysztof Lukaszuk, Izabela Woclawek-Potocka, Grzegorz Jakiel, Paulina Malinowska, Artur Wdowiak, Karolina Rozanska, Lukasz Rabalski
Format: Article
Language:English
Published: MDPI AG 2021-10-01
Series:Vaccines
Subjects:
COVID-19
vaccination
methotrexate
TNFis
autoimmune disease
AIIRD
Online Access:https://www.mdpi.com/2076-393X/9/10/1151

Internet

https://www.mdpi.com/2076-393X/9/10/1151

Similar Items